Sawai stock: Nomura cuts stake in Sawai stock by 1.12 points

Published on 10/24/2026 at 04:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sawai Group Holdings presented 20.5 billion tablets of theoretical capacity on October 2. Sawai stock has results scheduled for November 6.

Ownership and capacity shape the view

Nomura reduced its Sawai holding by 1.12 percentage points on October 22, 2026.
Sawai presented theoretical capacity of 20.5 billion tablets on October 2, 2026.
Revenue grew 4.3 percent year over year in the first quarter of fiscal 2027.

Sawai, JP3323040000, Illustration mit AI erstellt.

Sawai Group Holdings (ISIN JP3323040000) saw Nomura reduce its holding by 1.12 percentage points to 5.83 percent, according to Excite on October 22, 2026. The filing gives investors a fresh ownership signal as Sawai prepares to report its next quarterly results.

Ownership changes add context

The Nomura filing stated that the holding declined by 1.12 percentage points, while the remaining stake stood at 5.83 percent. The report identified Sawai Group Holdings as a company listed on the Tokyo Stock Exchange Prime Market and classified it in pharmaceuticals.

The ownership change follows an operational strategy centered on domestic generic medicines. Sawai Group Holdings focuses on research, manufacturing and commercialization, with Japan as its main operating market.

Three recent milestones

On June 30, 2026, revenue for the first quarter of fiscal 2027 rose 4.3 percent year over year, while profits and margins declined, according to Quartr. On October 2, 2026, the company presented theoretical group production capacity of 20.5 billion tablets, according to Logmi Finance. On October 22, 2026, the Nomura holding fell by 1.12 percentage points to 5.83 percent, as reported by Excite.

What does 20.5 billion tablets mean?

The capacity figure shows the scale of Sawai's supply investment. The company said its Second Kyushu Plant Step 2 could add 1.5 billion tablets, lifting internal capacity to 22.0 billion tablets during fiscal 2026, while longer-term plans target nearly 25.0 billion tablets by 2030, according to Logmi Finance. That expansion matters because the first-quarter comparison combined revenue growth with lower profits and margins.

Next reporting date

The next scheduled earnings report is November 6, 2026, according to TradingView. The release should clarify whether capacity investment and product launches are translating into improved profitability.

Operations remain the central question

Sawai's investor case now combines a measurable manufacturing expansion with a near-term profitability test. The 20.5 billion tablet capacity figure and the 4.3 percent first-quarter revenue increase point to scale, while the profit and margin decline keeps execution central.